NMRA Neumora Therapeutics Inc.
Price (delayed)
$0.9404
Market cap
$152.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.53
Enterprise value
$10.82M
Highlights
The debt has plunged by 65% YoY and by 32% from the previous quarter
The company's EPS has surged by 58% YoY but it fell by 28% QoQ
The net income is up by 17% since the previous quarter but it has declined by 3.3% year-on-year
Neumora Therapeutics's quick ratio has decreased by 43% YoY and by 4.3% QoQ
Neumora Therapeutics's equity has decreased by 39% YoY and by 10% QoQ
Key stats
What are the main financial stats of NMRA
Market
Valuations
Earnings
Shares outstanding
161.98M
Market cap
$152.32M
Enterprise value
$10.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$263.46M
Net income
-$243.79M
EBIT
-$243.61M
EBITDA
-$239.69M
Free cash flow
-$182.94M
Per share
Balance sheet
Liquidity
EPS
-$1.53
EPS diluted
-$1.53
Free cash flow per share
-$1.15
Book value per share
$1.78
Revenue per share
$0
TBVPS
$1.99
Total assets
$316.97M
Total liabilities
$29.91M
Debt
$1.85M
Equity
$287.06M
Working capital
$284.17M
Debt to equity
0.01
Current ratio
10.51
Quick ratio
10.33
Net debt/EBITDA
0.59
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-64%
Return on equity
-69%
Return on invested capital
-145.2%
Return on capital employed
-84.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NMRA stock price
How has the Neumora Therapeutics stock price performed over time
Intraday
2.97%
1 week
-13.72%
1 month
-39.72%
1 year
-93.17%
YTD
-91.13%
QTD
-5.96%
Financial performance
How have Neumora Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$263.46M
Net income
-$243.79M
Gross margin
N/A
Net margin
N/A
The net income is up by 17% since the previous quarter but it has declined by 3.3% year-on-year
Neumora Therapeutics's operating income has increased by 16% QoQ but it has decreased by 4.5% YoY
Growth
What is Neumora Therapeutics's growth rate over time
Valuation
What is Neumora Therapeutics stock price valuation
P/E
N/A
P/B
0.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 58% YoY but it fell by 28% QoQ
The stock's P/B is 91% below its last 4 quarters average of 5.5
Neumora Therapeutics's equity has decreased by 39% YoY and by 10% QoQ
Efficiency
How efficient is Neumora Therapeutics business performance
The ROE has soared by 97% YoY and by 6% from the previous quarter
The ROA has contracted by 25% YoY but it has grown by 7% from the previous quarter
NMRA's return on invested capital is up by 22% since the previous quarter and by 17% year-on-year
Dividends
What is NMRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NMRA.
Financial health
How did Neumora Therapeutics financials performed over time
NMRA's current ratio is down by 45% year-on-year and by 4.3% since the previous quarter
Neumora Therapeutics's quick ratio has decreased by 43% YoY and by 4.3% QoQ
The debt is 99% less than the equity
The debt has plunged by 65% YoY and by 32% from the previous quarter
Neumora Therapeutics's equity has decreased by 39% YoY and by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.